Tamsulosin

Flomax treats signs and symptoms of benign prostatic hyperplasia. It is not labeled to treat hypertension. Evaluate the cause of urinary symptoms because BPH and prostate cancer can coexist.

EAU 2026 offers alpha blockers as an off-label option for selected patients with distal ureteral stones 5–10 mm. Use only when active removal is not indicated and the patient understands the tradeoffs. Stop conservative treatment if infection, refractory pain, or worsening renal function develops. This guideline does not establish a U.S. tamsulosin approval or a universal stone-treatment dose.

Take 0.4 mg once daily about 30 minutes after the same meal each day. If response is insufficient after 2–4 weeks, the prescriber may increase to 0.8 mg once daily. If either regimen is interrupted for several days, restart with 0.4 mg once daily. Swallow capsules whole; do not open, crush, or chew.

No renal dose adjustment is specified, but CrCl below 10 mL/min/1.73 m² was not studied. Moderate hepatic impairment requires no adjustment; severe impairment was not studied. Review hypotension risk and interacting medicines before increasing to 0.8 mg.

Known hypersensitivity to tamsulosin or any capsule component is a contraindication. Strong CYP3A4 inhibitor combinations are directed against under dosage/warnings rather than listed in the formal contraindications section.

The selected U.S. label contains no boxed warning. Its syncope, interaction, priapism, and surgical warnings still require action.

Dizziness, abnormal ejaculation, rhinitis, and fatigue are reported in trials. Postmarketing reports include hypersensitivity, severe skin reactions, hypotension, arrhythmias, and IFIS; spontaneous reports cannot establish frequency. Excess dosing can cause marked hypotension requiring cardiovascular support, fluids or vasopressors as appropriate, and renal monitoring. Dialysis is unlikely to help because protein binding is high.

Do not combine with strong CYP3A4 inhibitors such as ketoconazole. Use caution with moderate CYP3A4 inhibitors (erythromycin), strong/moderate CYP2D6 inhibitors (paroxetine/terbinafine), known CYP2D6 poor metabolism, and cimetidine—especially above 0.4 mg. Simultaneous inhibition of both pathways may substantially increase exposure.

Do not combine with another alpha blocker. PDE5 inhibitors can produce symptomatic hypotension; review the combination and monitor. Warfarin interaction studies are inconclusive, and the label recommends caution rather than a predictable dose change.

Flomax is not indicated for women. Human pregnancy-risk and milk/infant-effect data are inadequate or absent; animal findings do not establish human safety. Ejaculatory changes can affect sexual function, and label fertility effects are based on animal studies, not a quantified human infertility risk. Off-label treatment during pregnancy or lactation requires a separate assessment.

There is no pediatric indication; trials in children with neurologic bladder dysfunction did not demonstrate efficacy. Older adults showed no overall trial difference, but greater sensitivity remains possible, warranting attention to dizziness and falls.

Renal impairment generally needs no dose adjustment; end-stage renal disease below CrCl 10 mL/min/1.73 m² remains unstudied. Moderate hepatic impairment needs no adjustment; no severe-hepatic regimen is established by the label.

Tamsulosin preferentially blocks alpha-1 receptors in the prostate, reducing the dynamic smooth-muscle component of bladder outlet obstruction and improving urine flow and BPH symptoms. This mechanism does not make it an approved antihypertensive.

Food changes absorption, supporting consistent meal timing. The drug is highly protein bound and metabolized mainly through CYP3A4 and CYP2D6. Less than 10% is excreted unchanged in urine. The apparent half-life with Flomax capsules is about 9–13 hours in healthy volunteers and 14–15 hours in the target population.

Assess urinary symptoms, response after the initial 2–4 weeks, blood-pressure symptoms, and medication interactions. Perform prostate-cancer assessment before treatment and periodically. Ask about cataract/glaucoma surgery, falls, severe sulfa allergy, and prior alpha-blocker exposure.

Rise carefully and avoid hazardous activities until the effect is known. Report fainting, troublesome ejaculation changes, or worsening urinary symptoms. Seek immediate help for a persistent painful erection, severe allergy, or severe skin reaction. Inform the eye surgeon even if treatment ended long ago. After several missed days contact the prescriber to resume the 0.4-mg regimen.

The source label describes Flomax 0.4-mg hard gelatin capsules with an olive-green cap and orange body, marked “Flomax 0.4 mg” and “BI 58.” The source manufacturer package is a 100-capsule bottle, NDC 0024-5837-01. The retrieved DailyMed record is a RedPharm repackaged label with its own NDC; its packaging should not be conflated with that source bottle. Other generic appearances vary.

The selected U.S. Flomax product is a 0.4-mg capsule; a 0.8-mg regimen uses two capsules. Do not treat different formulations or non-U.S. product strengths as interchangeable without checking their specific label.

Store at 25°C (77°F); excursions of 15–30°C (59–86°F) are permitted. Keep out of children’s reach and preserve capsules intact until use.